You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 368 REVEAL: Phase 1 dose-escalation study of NKTR-262, a novel TLR7/8 agonist, plus bempegaldesleukin: local innate immune activation and systemic adaptive immune expansion for treating solid tumors

Article metrics

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Clinical trials in progress
368 REVEAL: Phase 1 dose-escalation study of NKTR-262, a novel TLR7/8 agonist, plus bempegaldesleukin: local innate immune activation and systemic adaptive immune expansion for treating solid tumors

 

Online download statistics by month:

Online download statistics by month: November 2020 to October 2025

AbstractFullPdf
Nov 2020339032
Dec 2020129021
Jan 202150012
Feb 202140016
Mar 202186022
Apr 202178012
May 202129010
Jun 20210010
Jul 20210018
Aug 20210015
Sep 20210012
Oct 2021108036
Nov 2021120027
Dec 20216608
Jan 2022124011
Feb 2022116012
Mar 202292010
Apr 202215008
May 202210009
Jun 2022110013
Jul 20226601
Aug 20225807
Sep 20223802
Oct 20222204
Nov 20224403
Dec 20224205
Jan 20234405
Feb 20238005
Mar 2023126012
Apr 202358013
May 20238607
Jun 202374012
Jul 202374016
Aug 202374011
Sep 20236407
Oct 202368016
Nov 20238008
Dec 202310205
Jan 20241400
Feb 20248006
Mar 20246006
Apr 20248205
May 20248604
Jun 20246304
Jul 2024138016
Aug 2024134022
Sep 202460014
Oct 2024103028
Nov 202486014
Dec 2024102017
Jan 202592017
Feb 202522010
Mar 20250012
Apr 2025107
May 2025003
Jun 20250014
Jul 2025001
Oct 2025001
Total40600654